|
1
|
Carvalho AL, Pintos J, Schlecht NF,
Oliveira BV, Fava AS, Curado MP, Kowalski LP and Franco EL:
Predictive factors for diagnosis of advanced-stage squamous cell
carcinoma of the head and neck. Arch Otolaryngol Head Neck Surg.
128:313–318. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Ho AS, Kim S, Tighiouart M, Gudino C, Mita
A, Scher KS, Laury A, Prasad R, Shiao SL, Ali N, et al: Association
of quantitativemetastatic lymph node burden with survival in
hypopharyngeal and laryngeal cancer. JAMA Oncol. 4:985–989. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Zlotnik A and Yoshie O: Chemokines: A new
classification system and their role in immunity. Immunity.
12:121–127. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Proudfoot AEI: Chemokine receptors:
Multifaceted therapeutic targets. Nat Rev Immunol. 2:106–115. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Zhou Y, Larsen PH, Hao C and Yong VW:
CXCR4 is a major chemokine receptor on glioma cells and mediates
their survival. J Biol Chem. 277:49481–49487. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Burger JA and Kipps TJ: CXCR4: A key
receptor in the crosstalk between tumor cells and their
microenvironment. Blood. 107:1761–1767. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Balkwill F: Cancer and the chemokine
network. Nat Rev Cancer. 4:540–550. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Scala S, Ottaiano A, Ascierto PA, Cavalli
M, Simeone E, Giuliano P, Napolitano M, Franco R, Botti G and
Castello G: Expression of CXCR4 predicts poor prognosis in patients
with malignant melanoma. Clin Cancer Res. 11:1835–1841. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Barbero S, Bonavia R, Bajetto A, Porcile
C, Pirani P, Ravetti JL, Zona GL, Spaziante R, Florio T and
Schettini G: Stromal cell-derived factor 1alpha stimulates human
glioblastoma cell growth through the activation of both
extracellular signal-regulated kinases 1/2 and Akt. Cancer Res.
63:1969–1974. 2003.PubMed/NCBI
|
|
10
|
Müller A, Homey B, Soto H, Ge N, Catron D,
Buchanan ME, McClanahan T, Murphy E, Yuan W, Wagner SN, et al:
Involvement of chemokine receptors in breast cancer metastasis.
Nature. 410:50–56. 2001. View
Article : Google Scholar : PubMed/NCBI
|
|
11
|
Taichman RS, Cooper C, Keller ET, Pienta
KJ, Taichman NS and McCauley LK: Use of the stromal cell-derived
factor-1/CXCR4 pathway in prostate cancer metastasis to bone.
Cancer Res. 62:1832–1837. 2002.PubMed/NCBI
|
|
12
|
Jiang YP, Wu XH, Shi B, Wu WX and Yin GR:
Expression of chemokine CXCL12 and its receptor CXCR4 in human
epithelial ovarian cancer: An independent prognostic factor for
tumor progression. Gynecol Oncol. 103:226–233. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Chen GS, Yu HS, Lan CC, Chow KC, Lin TY,
Kok LF, Lu MP, Liu CH and Wu MT: CXC chemokine receptor CXCR4
expression enhances tumorigenesis and angiogenesis of basal cell
carcinoma. Br J Dermatol. 154:910–918. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Tan CT, Chu CY, Lu YC, Chang CC, Lin BR,
Wu HH, Liu HL, Cha ST, Prakash E, Ko JY and Kuo ML: CXCL12/CXCR4
promotes laryngeal and hypopharyngeal squamous cell carcinoma
metastasis through MMP-13-dependent invasion via the ERK1/2/AP-1
pathway. Carcinogenesis. 29:1519–1527. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Samara GJ, Lawrence DM, Chiarelli CJ,
Valentino MD, Lyubsky S, Zucker S and Vaday GG: CXCR4-mediated
adhesion and MMP-9 secretion in head and neck squamous cell
carcinoma. Cancer Lett. 214:231–241. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Hong JS, Pai HK, Hong KO, Kim MA, Kim JH,
Lee JI, Hong SP and Hong SD: CXCR-4 knockdown by small interfering
RNA inhibits cell proliferation and invasion of oral squamous cell
carcinoma cells. J Oral Pathol Med. 38:214–219. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Rehman AO and Wang CY: CXCL12/SDF-1 alpha
activates NF-kappaB and promotes oral cancer invasion through the
Carma3/Bcl10/Malt1 complex. Int J Oral Sci. 1:105–118. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Yu T, Wu Y, Helman JI, Wen Y, Wang C and
Li L: CXCR4 Promotes oral squamous cell carcinoma migration and
invasion through inducing expression of MMP-9 and MMP-13 via the
ERK signaling pathway. Mol Cancer Res. 9:161–172. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Ishikawa T, Nakashiro KI, Hara S, Klosek
SK, Li C, Shintani S and Hamakawa H: CXCR4 expression is associated
with lymph-node metastasis of oral squamous cell carcinoma. Int J
Oncol. 28:61–66. 2006.PubMed/NCBI
|
|
20
|
Katayama A, Ogino T, Bandoh N, Nonaka S
and Harabuchi Y: Expression of CXCR4 and its down-regulation by
IFN-gamma in head and neck squamous cell carcinoma. Clin Cancer
Res. 11:2937–2946. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
De-Colle C, Mönnich D, Welz S, Boeke S,
Sipos B, Fend F, Mauz PS, Tinhofer I, Budach V, Jawad JA, et al:
SDF-1/CXCR4 expression in head and neck cancer and outcome after
postoperative radiochemotherapy. Clin Transl Radiat Oncol. 5:28–36.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Knopf A, Bahadori L, Fritsche K, Piontek
G, Becker CC, Knolle P, Krüger A, Bier H and Li Y: Primary
tumor-associated expression of CXCR4 predicts formation of local
and systemic recurrency in head and neck squamous cell carcinoma.
Oncotarget. 8:112739–112747. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Caudroy S, Polette M, Tournier JM, Burlet
H, Toole B, Zucker S and Birembaut P: Expression of the
extracellular matrix metalloproteinase inducer (EMMPRIN) and the
matrix metalloproteinase-2 in bronchopulmonary and breast lesions.
J Histochem Cytochem. 47:1575–1580. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Suzuki S, Sato M, Senoo H and Ishikawa K:
Direct cell-cell interaction enhances pro-MMP-2 production and
activation in co-culture of laryngeal cancer cells and fibroblasts:
Involvement of EMMPRIN and MT1-MMP. Exp Cell Res. 293:259–266.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Hibino T, Sakaguchi M, Miyamoto S,
Yamamoto M, Motoyama A, Hosoi J, Shimokata T, Ito T, Tsuboi R and
Huh NH: S100A9 is a novel ligand of EMMPRIN that promotes melanoma
metastasis. Cancer Res. 73:172–183. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Takahashi M, Suzuki S and Ishikawa K:
Cyclophilin A-EMMPRIN interaction induces invasion of head and neck
squamous cell carcinoma. Oncol Rep. 27:198–203. 2012.PubMed/NCBI
|
|
27
|
Suzuki S, Honda K, Nanjo H, Iikawa N,
Tsuji T, Kawasaki Y, Yamazaki K, Sato T, Saito H, Shiina K and
Ishikawa K: CD147 expression correlates with lymph node metastasis
inT1-T2 squamous cell carcinoma of the tongue. Oncol Lett.
14:4670–4676. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Shi WP, Ju D, Li H, Yuan L, Cui J, Luo D,
Chen ZN and Bian H: CD147 promotes CXCL1 expression and modulates
liver fibrogenesis. Int J Mol Sci. 19:11452018. View Article : Google Scholar
|
|
29
|
Peng C, Zhang S, Lei L, Zhang X, Jia X,
Luo Z, Huang X, Kuang Y, Zeng W, Su J and Chen X: Epidermal CD147
expression plays a key role in IL-22-induced psoriatic dermatitis.
Sci Rep. 7:441722017. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Bordador LC, Li X, Toole B, Chen B, Regezi
J, Zardi L, Hu Y and Ramos DM: Expression of emmprin by oral
squamous cell carcinoma. Int J Cancer. 85:347–352. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Koga K, Nabeshima K, Aoki M, Kawakami T,
Hamasaki M, Toole BP, Nakayama J and Iwasaki H: Emmprin in
epithelioid sarcoma: Expression in tumor cell membrane and
stimulation of MMP-2 production in tumor-associated fibroblasts.
Int J Cancer. 120:761–768. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Ishikawa T, Nakashiro KI, Klosek SK, Goda
H, Hara S, Uchida D and Hamakawa H: Hypoxia enhances CXCR4
expression by activating HIF-1 in oral squamous cell carcinoma.
Oncol Rep. 21:707–712. 2009.PubMed/NCBI
|
|
33
|
Asakage T, Yokose T, Mukai K, Tsugane S,
Tsubono Y, Asai M and Ebihara S: Tumor thickness predicts cervical
metastasis in patients with stage I/II carcinoma of the tongue.
Cancer. 82:1443–1448. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Koppikar P, Choi SH, Egloff AM, Cai Q,
Suzuki S, Freilino M, Nozawa H, Thomas SM, Gooding WE, Siegfried JM
and Grandis JR: Combined inhibition of c-Src and epidermal growth
factor receptor abrogates growth and invasion of head and neck
squamous cell carcinoma. Clin Cancer Res. 14:4284–4291. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Jung YH, Lee DY, Cha W, Kim BH, Sung MW,
Kim KH and Ahn SH: Antitumor effect of CXCR4 antagonist AMD3100 on
the tumorigenic cell line of BHP10-3 papillary thyroid cancer
cells. Head Neck. 38:1479–1486. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Spano JP, Andre F, Morat L, Sabatier L,
Besse B, Combadiere C, Deterre P, Martin A, Azorin J, Valeyre D, et
al: Chemokine receptor CXCR4 and early-stage non-small cell lung
cancer: Pattern of expression and correlation with outcome. Ann
Oncol. 15:613–617. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Koishi K, Yoshikawa R, Tsujimura T,
Hashimoto-Tamaoki T, Kojima S, Yanagi H, Yamamura T and Fujiwara Y:
Persistent CXCR4 expression after preoperative chemoradiotherapy
predicts early recurrence and poor prognosis in esophageal cancer.
World J Gastroenterol. 12:7585–7590. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Zhou W, Guo S, Liu M, Burow ME and Wang G:
Targeting CXCL12/CXCR4 axis in tumor immunotherapy. Curr Med Chem.
26:3026–3041. 2017. View Article : Google Scholar
|
|
39
|
Jung MJ, Rho JK, Kim YM, Jung JE, Jin YB,
Ko YG, Lee JS, Lee SJ, Lee JC and Park MJ: Upregulation of CXCR4 is
functionally crucial for maintenance of stemness in drug-resistant
non-small cell lung cancer cells. Oncogene. 32:209–221. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Es-Haghi M, Soltanian S and Dehghani H:
Perspective: Cooperation of Nanog, NF-κΒ, and CXCR4 in a regulatory
network for directed migration of cancer stem cells. Tumour Biol.
37:1559–1565. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
De-Colle C, Menegakis A, Mönnich D, Welz
S, Boeke S, Sipos B, Fend F, Mauz PS, Tinhofer I, Budach V, et al:
SDF-1/CXCR4 expression is an independent negative prognostic
biomarker in patients with head and neck cancer after primary
radiochemotherapy. Radiother Oncol. 126:125–131. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Wolff HA, Rolke D, Rave-Fränk M, Schirmer
M, Eicheler W, Doerfler A, Hille A, Hess CF, Matthias C, Rödel RM
and Christiansen H: Analysis of chemokine and chemokine receptor
expression in squamous cell carcinoma of the head and neck (SCCHN)
cell lines. Radiat Environ Biophys. 50:145–154. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Zhu C, Pan Y, He B, Wang B, Xu Y, Qu L,
Bao Q, Tian F and Wang S: Inhibition of CD147 gene expression via
RNA interference reduces tumor cell invasion, tumorigenicity and
increases chemosensitivity to cisplatin in laryngeal carcinoma Hep2
cells. Oncol Rep. 25:425–432. 2011.PubMed/NCBI
|
|
44
|
Vu TH and Werb Z: Matrix
metalloproteinases: Effectors of development and normal physiology.
Genes Dev. 14:2123–2133. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Rosenthal EL, Shreenivas S, Peters GE,
Grizzle WE, Desmond R and Gladson CL: Expression of extracellular
matrix metalloprotease inducer in laryngeal squamous cell
carcinoma. Laryngoscope. 113:1406–1410. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Suzuki S, Toyoma S, Tsuji T, Kawasaki Y
and Yamada T: CD147 mediates transforming growth factor-β1-induced
epithelial-mesenchymal transition and cell invasion in squamous
cell carcinoma of the tongue. Exp Ther Med. 17:2855–2860.
2019.PubMed/NCBI
|
|
47
|
Landras A, de Moura CR, Jouenne F, Lebbe
C, Menashi S and Mourah S: CD147 is a promising target of tumor
progression and a prognostic biomarker. Cancers (Basel). 11:2019.
View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Dean NR, Newman JR, Helman EE, Zhang W,
Safavy S, Weeks DM, Cunningham M, Snyder LA, Tang Y, Yan L, et al:
Anti-EMMPRIN monoclonal antibody as a novel agent for therapy of
head and neck cancer. Clin Cancer Res. 15:4058–4065. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Vermorken JB, Herbst RS, Leon X, Amellal N
and Baselga J: Overview of the efficacy of cetuximab in recurrent
and/or metastatic squamous cell carcinoma of the head and neck in
patients who previously failed platinum-based therapies. Cancer.
112:2710–2719. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Nozawa H, Howell G, Suzuki S, Zhang Q, Qi
Y, Klein-Seetharaman J, Wells A, Grandis JR and Thomas SM: Combined
inhibition of PLC{gamma}-1 and c-Src abrogates epidermal growth
factor receptor-mediated head and neck squamous cell carcinoma
invasion. Clin Cancer Res. 14:4336–4344. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Suzuki S and Ishikawa K: Combined
inhibition of EMMPRIN and epidermal growth factor receptor prevents
the growth and migration of head and neck squamous cell carcinoma
cells. Int J Oncol. 44:912–917. 2014. View Article : Google Scholar : PubMed/NCBI
|
